Information Provided By: 
Fly News Breaks for November 10, 2017
TROV
Nov 10, 2017 | 08:38 EDT
As reported earlier, Maxim analyst Jason Kolbert downgraded Trovagene to Hold from Buy and removed his $4 price target. Kolbert says the company closed Q3 with $7.4M in cash, which is likely to be much lower today. The analyst says Trovagene needs to raise capital in order to gain a stronger position to transition to a therapeutics company focused on PCM-075.
News For TROV From the Last 2 Days
There are no results for your query TROV
